Compare ADMA Biologics Inc (ADMA) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Ecopetrol SA — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Ecopetrol SA trades at $17.06 (market cap $34.97B). The key difference: Ecopetrol SA is far larger — about 16× ADMA Biologics Inc's market cap, and Ecopetrol SA pays a 3.81% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EC | |
|---|---|---|
Market Cap | $2.18B | $34.97B |
Sector | Health | Energy |
52-Week High | $20.38 | $17.40 |
52-Week Low | $7.60 | $8.53 |
Enterprise Value | $2.25B | $65.28B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Ecopetrol (EC) trades at $16.78, down 3.56% on the day, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators are neutral. Fundamentally, revenue and net income have declined from 2022 peaks, though Q2 2026 earnings beat expectations. Recent news includes a cybersecurity incident and expansion efforts in Brazil, adding to volatility. Valuation ratios like P/E of 11.11 and P/S of 0.97 suggest potential undervaluation relative to historical metrics.
The outlook for EC is cautious; analyst consensus is mixed with a $15 price target below the current price. Risks include declining revenue trends, high debt levels, and operational disruptions from recent cyber threats. Opportunities lie in cost management and strategic acquisitions, but investor sentiment remains divided. The stock's near-term performance hinges on execution stability and energy market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
